P656: Plasma Inflammation-related Proteins Predict the Therapeutic Effect of 5-ASA in Patients with Ulcerative ColitisECCO'24Year: 2024
Authors: Dang, Y.(1)*;Xu, X.(1);Zhou, M.(1);Xu, C.(1);Huang, X.(1);Xu, F.(1);Wang, Z.(1);Wang, C.(1);Zhu, S.(1);Li, P.(1);Zhang, S.(1);Shi, H.(1);
(1)Capital Medical University- Beijing Friendship Hospital, Department of gastroenterology, Beijing, China;
P657: Persistence of subcutaneous infliximab after two years of the switch from intravenous infliximab to subcutaneous infliximab in Inflammatory Bowel Disease patientsECCO'24Year: 2024
Authors: Huguet, J.M.(1)*;Iborra, M.(2);Marti, L.(3);Bosca-Watts, M.M.(4);Ramirez, J.J.(5);Ruiz, L.(1);Sanchis, L.(6);Garrido, A.(2);Alemany, G.(3);Suria, C.(4);Paredes, J.M.(7);
(1)Hospital General Universitario de Valencia, Gastroenterology, Valencia, Spain;(2)Hospital Universitari i Politecnic la Fe de Valencia, Gastroenterology, Valencia, Spain;(3)Hospital Francesc de Borja de Gandia, Gastroenterology, Valencia, Spain;(4)Hospital Clinico Universitario de Valencia, Gastroenterology, Valencia, Spain;(5)Hospital Lluis Alcanyis de Xativa, Gastroenterology, Valencia, Spain;(6)Hospital de Sagunto, Gastroenterology, Valencia, Spain;(7)Hospital Universitario Dr. Peset de Valencia, Gastroenterology, Valencia, Spain;
P658: Safety and efficacy of MH002, an optimized live biotherapeutic product, for the treatment of mild to moderate ulcerative colitis: a first-in-disease, double-blind, randomized clinical trialECCO'24Year: 2024
Authors: Vermeire, S.(1)*;Dewint, P.(2);Vansteelant, M.(2);Peterka, M.(3);Štěpek, D.(4);Kierkuś, J.(5);Wiernicka, A.(5);Napora, P.(6);Wolański , Ł.(7);Kopoń, A.(8);Magro, F.(9);Pinheiro, I.(10);Possemiers, S.(10);Haazen, L.(10);Bolca, S.(10);
(1)University hospitals Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;(2)AZ Maria Middelares Gent, Department of Gastroenterology, Ghent, Belgium;(3)Nemocnice Slany, Gastroenterologická a hepatologická ambulance, Slany, Czech Republic;(4)Vojenska nemocnice Brno, Interni oddeleni, Brno, Czech Republic;(5)The Children’s Memorial Health Institute, Department of Gastroenterology- Hepatology- Feeding Disorders and Pediatrics, Warsaw, Poland;(6)Centrum Badań Klinicznych, Gastroenterology, Wroclaw, Poland;(7)Samodzielny Publiczny Zakład Opieki Zdrowotnej w Łęcznej, Oddział Gastroenterologiczny, Łęczna, Poland;(8)Centrum Gastrologii I Endoskopii, Gastromed, Toruń, Poland;(9)Faculty of Medicine of the University of Porto, Cintesis@RISE, Porto, Portugal;(10)MRM Health NV, Research & Development, Zwijnaarde, Belgium;
P659: Prognostic markers in Treat-to-Target for Crohn’s Disease- an Asian institution’s experienceECCO'24Year: 2024
Authors: Jiang, B.(1)*;Leong, J.(1);Ong, J.(1);Ang, T.L.(1);Wang, L.M.(2);Tan, C.K.(1);
(1)Changi General Hospital, Gastroenterology and Hepatology, Singapore, Singapore;(2)Changi General Hospital, Pathology, Singapore, Singapore;
P660: Serum Leucine-rich Alpha-2 Glycoprotein Can be a Biomarker for Selecting Anti-Cytokine Biologics in Patients with Inflammatory Bowel Disease: A Multicentre Prospective Cohort StudyECCO'24Year: 2024
Authors: Amano, T.(1)*;Yoshihara, T.(1);Shinzaki, S.(2);Sakakibara, Y.(3);Yamada, T.(4);Osugi, N.(5);HIyama, S.(6);Murayama, Y.(7);Ogiyama, H.(8);Nagaike, K.(9);Tujii, Y.(1);Asakura, A.(1);Tashiro, T.(1);Tani, M.(1);Otake-Kasamoto, Y.(1);Inoue, T.(1);Yonezawa, A.(10);Iijima, H.(11);Hayashi, Y.(1);Takehara, T.(1);
(1)Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Suita, Japan;(2)Hyogo Medical University, Department of Gastroenterology, Nishinomiya, Japan;(3)National Hospital Organization Osaka National Hospital, Department of Gastroenterology, Osaka, Japan;(4)Osaka Rosai Hospital, Department of Gastroenterology and Hepatology, Sakai, Japan;(5)Toyonaka Municipal Hospital, Department of Gastroenterology, Toyonaka, Japan;(6)Japan Community Healthcare Organization Osaka Hospital, Department of Gastroenterology, Osaka, Japan;(7)Itami City Hospital, Department of Gastroenterology and Hepatology, Itami, Japan;(8)Ikeda Municipal Hospital, Department of Gastroenterology, Ikeda, Japan;(9)Suita Municipal Hospital, Department of Gastroenterology and Hepatology, Suita, Japan;(10)Keio University, Division of Integrative Clinical Pharmacology- Faculty of Pharmacy, Tokyo, Japan;(11)Osaka Police Hospital, Department of Internal Medicine, Osaka, Japan;the Osaka Gut Forum
P661: Ustekinumab in Crohn’s disease: A three-year multicentre prospective study from Hungary - Assessing efficacy, drug sustainability, and safetyECCO'24Year: 2024
Authors: Barkai, L.J.(1)*;Gonczi, L.(1);Farkas, K.(2);Farkas, B.(2);Molnar, T.(2);Szamosi, T.(3);Schafer, E.(3);Golovics, P.(3);Juhasz, M.(4);Patai, A.(5);Vincze, A.(6);Sarlos, P.(6);Farkas, A.(7);Dubravcsik, Z.(7);Toth, T.G.(8);Miheller, P.(9);LakatosPhD, P.L.(10);Ilias, A.(1);
(1)Semmelweis University, Department of Medicine and Oncology, Budapest, Hungary;(2)University of Szeged, Department of Medicine, Szeged, Hungary;(3)Medical Centre- Hungarian Defence Forces, Department of Gastroenterology, Budapest, Hungary;(4)St. Margit Hospital, Department of Medicine, Budapest, Hungary;(5)Markusovszky Hospital, Department of Medicine and Gastroenterology, Szombathely, Hungary;(6)Medical School- University of Pecs, First Department of Medicine, Pecs, Hungary;(7)Bács-Kiskun County Hospital, Department of Gastroenterology, Kecskemet, Hungary;(8)St. Janos Hospital, Department of Gastroenterology, Budapest, Hungary;(9)Semmelweis University, Department of Surgery- Transplantation and Gastroenterology, Budapest, Hungary;(10)Mcgill University Health Center, IBD Centre, Montréal, Canada;
P662: Discontinuation of biologic therapy in Inflammatory Bowel Disease: longer term outcomes.ECCO'24Year: 2024
Authors: Al-Talib, I.(1)*;Iqbal, M.(1);Slater, J.(1);Bates, B.(1);Jones, J.(1);Rattehalli, D.(1);King, D.(1);De Silva, S.(1);
(1)The Dudley Group NHS Foundation Trust, Gastroenterology, Dudley, United Kingdom;
P663: Efficacy of jak inhibitors in inflammatory bowel disease patients with extraintestinal manifestations– Retrospective studyECCO'24Year: 2024
Authors: Livne Margolin, M.(1)*;González Lama2, Y.(2);Koutroubakis, I.(3);Drygiannakis, I.(4);Shitrit, A.(5);Goldenberg , R.(5);Farkas, K.(6); Molnar , T.(6);Ivány, E.(7);Amiot, A.(8); Carbonnel, F.(9);Girod, P.(10);Doherty, G.(11);Mateescu, B.(12);Ben-Horin1, S.(13);Kopylov, U.(1);
(1)Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;(2)Hospital Universitario Puerta de Hierro, Gastroenterology and Hepatology Dpt, Madrid, Spain;(3)hospital heraklion, Gastroenterology department, Crete, Greece;(4)Heraklion University Hospital, Department of gastroenterology, Crete, Greece;(5)Shaare Zedek Medical Center, department of gastroenterology, Jerusalem, Israel;(6)University of Szeged, Department of medicine, Szeged, Hungary;(7)Aranyklinika medical center, department of gastroenterology, Szeged, Hungary;(8)University Paris Est Creteil, Department of gastroenterology, Paris, France;(9)University of Paris Est Creteil, Department of gastroenterology, Paris, France;(10)St. Vincent’s University Hospital, Department of gastroenterology, Dublin, Ireland;(11)St. Vincent@E@s University Hospital, Department of Gastroenterology- Centre for Colorectal Disease, Dublin, Ireland;(12)Colentina Clinical Hospital, Gastroenterology Department, Bucharest, Romania;(13)Sheba medical center, Department of gastroenterolgy, Ramat Gan, Israel;
P665: Statins use and the risk of colorectal cancer in patients with inflammatory bowel disease: A Systematic review and meta-analysisECCO'24Year: 2024
Authors: Jung, B.W.(1);Lee, W.M.(2)*;Choi , S.(3);Lee, H.S.(4);ParkAssistant professor, J.J.(3);
(1)Hanyang University Guri Hospital- Hanyang University College of Medicine, Internal Medicine, Guri, Korea- Republic Of;(2)SoonChunHyang University Hospital, Internal medicine, Bucheon, Korea- Republic Of;(3)Severance Hospital- Yonsei University College of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(4)Yonsei University College of Medicine, Biostatics Collaboration Unit, Seoul, Korea- Republic Of;
P666: Accuracy of information given by ChatGPT for patients with Inflammatory Bowel Disease in relation to ECCO guidelinesECCO'24Year: 2024
Authors: Farrugia, Y.(1)*;Sciberras, M.(1);Gordon, H.(2);Furfaro, F.(3);Allocca, M.(3);Torres, J.(4);Arebi, N.(5);Fiorino , G.(3);Iacucci , M.(6);Verstockt , B.(7);Magro, F.(8);Katsanos , K.(9);Fenech, V.A.(1);Chetcuti Zammit , S.(1);Ellul, P.(1);
(1)Mater Dei Hospital- Malta, Department of Medicine- Division of Gastroenterology, Msida, Malta;(2)Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom;(3)IRCCS OSPEDALE San Raffaele, Department of Gastroenterology and Endoscopy, Milan, Italy;(4)Hospital Beatriz Ângelo, Division of Gastroenterology, Loures, Portugal;(5)St Mark@E@s National Bowel Hospital, Department of Inflammatory Bowel Disease, London, United Kingdom;(6)School of Medicine University College Cork, Gastroenterology, Cork, Ireland;(7)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(8)CINTESIS@RISE, Faculty of Medicine of the University of Porto, Porto, Portugal;(9)University of Ioannina School of Health Sciences, Division of Gastroenterology- Department of Internal Medicine, Ioannina, Greece;
P667: Benefit of 5-ASA continuation on UC disease outcomes following initiation of a biologicECCO'24Year: 2024
Authors: Tomasic, V.(1)*;Biscanin, A.(2,3);Cacic, P.(1);Babic, F.(1);Burcul, I.(4);Dorosulic, Z.(1);Kralj, D.(1);Ogresta Kordej, D.(1);Hrabar, D.(1,3);
(1)University Hospital Centre Sestre milosrdnice, Department of gastroenterology and hepatology, Zagreb, Croatia;(2)University Hospital Center Sestre milosrdnice, Department of gastroenterology and hepatology, Zagreb, Croatia;(3)University of Zagreb- School of Medicine, Internal medicine, Zagreb, Croatia;(4)General hospital Karlovac, Division of Internal medicine, Karlovac, Croatia;
P668: Dashboard-guided anti-TNF induction as an effective proactive strategy in Inflammatory Bowel Disease@E@s treatment.ECCO'24Year: 2024
Authors: Céspedes Martínez, E.(1)*;Robles-Alonso, V.(1);Herrera-De Guise, C.(1);Mayorga, L.(1);Serra, X.(1);Pérez , Z.(1);Oller, E.(1);Larrosa, M.(2);García-García, S.(2);Casellas, F.(1);Borruel, N.(1);
(1)Hospital Universitario Vall d@E@Hebron, Unitat d@E@Atenció Crohn-Colitis UACC- Gastroenterology Department, Barcelona, Spain;(2)Hospital Universitario Vall d@E@Hebron, Pharmacokinetic and pharmacogenetic Unit- Pharmacy Department, Barcelona, Spain;
P669: Efficacy of Ustekinumab-based integrated medicine therapy in patients with symptomatic stricturing Crohn@E@s disease: a multicentre, prospective, observational cohort studyECCO'24Year: 2024
Authors: Liu, J.(1);Hu, W.(1);Li, S.(2);Xu, D.(1);Wu, Q.(1);Chen, Y.(3)*;
(1)The Second Affiliated Hospital of Zhejiang University School of Medicine, Gastroenterology Department, Hangzhou, China;(2)The Second Affiliated Hospital of Zhejiang University School of Medicine, Nursing Department, Hangzhou, China;(3)The Second Affiliated Hospital- Zhejiang University School of Medicine, Inflammatory Bowel Disease Center- Department of Gastroenterology, Hangzhou, China;
P672: Occurrence of malignancy among infliximab biosimilar and bio-originator initiators in Canada: a comparative population-based analysisECCO'24Year: 2024
Authors: Birck, M.G.(1);Lukusa, L.(1);Singh, H.(2);Narula, N.(3);Targownik, L.E.(4);Leung, Y.(5);Afif, W.(6)*;Bernatsky, S.(1);
(1)Research Institute of the McGill University Health Centre, Centre for Outcomes Research and Evaluation, Montreal, Canada;(2)University of Manitoba, Max Rady College of Medicine, Winnipeg, Canada;(3)Hamilton Health Sciences, Division of Gastroenterology and Hepatology, Hamilton, Canada;(4)Mount Sinai Hospital, Division of Gastroenterology and Hepatology, Toronto, Canada;(5)University of British Columbia, Department of Medicine and Division of Gastroenterology, Vancouver, Canada;(6)McGill University, Division of Gastroenterology and Hepatology, Montreal, Canada;
P673: Accelerated intravenous ustekinumab dosing as rescue therapy in Moderate- Severe Ulcerative ColitisECCO'24Year: 2024
Authors: Muñoz Villafranca, M.D.C.(1)*;Arreba, P.(1);Buendia, L.(1);Higuera, R.O.(1);López, M.L.(1);Prado, N.F.(1);Irusta, L.(1);Jiménez, M.A.(1);Aldama, M.(1);Santacruz, M.(1);Perez, A.(1);Rodriguez, P.(1);Bilbao, A.(2);Ortiz de Zárate, J.(1);
(1)Hospital Universitario de Basurto, Gastroenterology, Bilbao, Spain;(2)Hospital Universitario de Basurto, Research Unit, Bilbao, Spain;
P674: Real-world experiences of switching to subcutaneous formulation in IBD patients on maintenance vedolizumab treatmentECCO'24Year: 2024
Authors: Bacsur, P.(1)*;Resál, T.(1);Farkas, B.(1);Sarlós, P.(2);Iliás, Á.(3);Kata, D.(4);Bálint, A.(1);Fábián, A.(1);Bor, R.(1);Szepes, Z.(1);Molnár, T.(1);Farkas, K.(1);
(1)Albert Szent-Györgyi Medical School- University of Szeged, Department of Medicine, Szeged, Hungary;(2)University of Pécs, Division of Gastroenterology- First Department of Medicine, Pécs, Hungary;(3)Semmelweis University, First Department of Medicine, Budapest, Hungary;(4)Albert Szent-Györgyi Medical School- University of Szeged, Institute of Laboratory Medicine, Szeged, Hungary;
P675: Comparative efficacy of Infliximab, Adalimumab, and Ustekinumab in patients with biologics naive Crohn@E@s disease：a retrospective observational single-center studyECCO'24Year: 2024
Authors: Sakurai, K.(1)*;Takahashi, S.(1);Fujihata, K.(1);Watanabe, R.(1);Nishimura, Y.(1);Yamada, R.(1);Sawada, K.(1);Sano, I.(1);Oda, H.(1);Miyagishima, T.(1);
(1)Kushiro Rosai Hospital, Department of Gastroenterology, Kushiro City- Hokkaido, Japan;
P676: Unveiling the impact on in utero exposure to biologic treatments for inflammatory bowel disease (IBD) on children@E@s psychomotor development: Insights from the DUMBO registry of GETECCU.ECCO'24Year: 2024
Authors: Palomino Pérez, L.M.(1)*;Velasco Rodríguez-Belvís, M.(1);Brenes Ruiz, Y.(2);Leo-Carnerero, E.(3);Calviño Suarez, C.(4);Rivero, M.(5);Calvo, M.(6);Arroyo, M.T.(7);Fernández-Clotet, A.(8);Pérez-Martínez, I.(9);Masedo González, Á.(10);Hernández, V.(11);Ruiz-Cerulla, A.(12);López Serrano, P.(13);Vega, P.(14);Rodríguez-Lago, I.(15);Vicente Lidón, R.(16);De Jorge, M.Á.(17);Guerra, I.(18);Arias García, L.(19);Molina Arriero, G.(20);Hervías Cruz, D.(21);Busquets, D.(22);Gutiérrez Casbas, A.(23);Van Domselaar, M.(24);Valldosera Gomis, G.(25);Vázquez Morón, J.M.(26);Piqueras Cano, M.(27);Lucendo, A.J.(28);Martín Arranz, M.D.(29);Ramírez de la Piscina, P.(30);Martínez Tirado, M.D.P.(31);Robles Alonso, V.(32);Marín Pedrosa, S.(33);Camargo Camero, R.(34);Armesto Gonzalez, E.(35);García-Salido, A.(36);Muñoz Codoceo, R.(1);Gisbert*, J.P.(2);Chaparro*, M.(2);
(1)Hospital Infantil Universitario Niño Jesús, Gastroenterology and Nutrition Unit, Madrid, Spain;(2)Hospital Universitario de La Princesa. Instituto de Investigación Sanitaria Princesa IIS-IP- and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology Unit, Madrid, Spain;(3)Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain;(4)Complexo Hospitalario Universitario de Santiago de Compostela, Gastroenterology Unit, Santiago de Compostela, Spain;(5)Hospital Universitario Marqués de Valdecilla e IDIVAL, Gastroenterology Unit, Santander, Spain;(6)Hospital Universitario Puerta de Hierro, Gastroenterology Unit, Majadahonda, Spain;(7)Hospital Clínico Universitario Lozano Blesa. IIS Aragón y CIBERehd, Gastroenterology Unit, Zaragoza, Spain;(8)Hospital Clinic de Barcelona. Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas CIBERehd. Institut d@E@Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, Gastroenterology Unit, Barcelona, Spain;(9)Hospital Universitario Central de Asturias. Diet- Microbiota and Health Group. Instituto de Investigación Sanitaria del Principado de Asturias ISPA., Gastroenterology Unit, Oviedo, Spain;(10)Hospital Universitario 12 de octubre, Gastroenterology Unit, Madrid, Spain;(11)Xerencia Xestión Integrada de Vigo- SERGAS. Grupo de Investigación de Patología Digestiva. Instituto de Investigación Sanitaria Galicia Sur IIS Galicia Sur. SERGAS UVIGO, Gastroenterology Unit, Vigo, Spain;(12)Hospital Universitario de Bellvitge- L@E@Hospitalet de Llobregat, Gastroenterology Unit, Barcelona, Spain;(13)Hospital Universitario Fundación Alcorcón, Gastroenterology Unit, Madrid, Spain;(14)Complexo Hospitalario Universitario de Ourense, Gastroenterology Unit, Ourense, Spain;(15)Hospital Universitario de Galdakao. Biobizkaia Health Research Institute, Gastroenterology Unit, Bizkaia, Spain;(16)Hospital Universitario Miguel Servet, Gastroenterology Unit, Zaragoza, Spain;(17)Hospital Universitario de Cabueñes, Gastroenterology Unit, Asturias, Spain;(18)Hospital Universitario de Fuenlabrada, Gastroenterology Unit, Madrid, Spain;(19)Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain;(20)Complejo Hospitalario Universitario de Ferrol, Gastroenterology Unit, A Coruña, Spain;(21)Hospital General Universitario de Ciudad Real, Gastroenterology Unit, Ciudad Real, Spain;(22)Hospital Trueta de Girona, Gastroenterology Unit, Girona, Spain;(23)Hospital General Universitario Dr. Balmis Alicante. ISABIAL- CIBERehd, Gastroenterology Unit, Alicante, Spain;(24)Hospital Universitario de Torrejón- Universidad Francisco de Vitoria, Gastroenterology Unit, Madrid, Spain;(25)Hospital Universitario Joan XXIII, Gastroenterology Unit, Tarragona, Spain;(26)Hospital Universitario Juan Ramón Jimenez, Gastroenterology Unit, Huelva, Spain;(27)Consorci Sanitari de Terrassa CST, Gastroenterology Unit, Barcelona, Spain;(28)Hospital General de Tomelloso. Instituto de Investigación Sanitaria La Princesa- Spain- Instituto de Investigación Sanitaria de Castilla-La Mancha IDISCAM- Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Unit, Ciudad Real, Spain;(29)Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain;(30)Hospital Universitario de Álava, Gastroenterology Unit, Álava, Spain;(31)Hospital Clínico Universitario San Cecilio, Gastroenterology Unit, Granada, Spain;(32)Hospital Vall d´Hebrón, Gastroenterology Unit, Barcelona, Spain;(33)Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain;(34)Hospital Universitario Virgen de La Victoria, Gastroenterology Unit, Málaga, Spain;(35)Hospital Universitario San Agustín, Gastroenterology Unit, Avilés, Spain;(36)Hospital Infantil Universitario Niño Jesús, Intensive Care Unit, Madrid, Spain;On behalf of the DUMBO project of GETECCU. *Authors share senior authorship
P677: The Oxford Anti-TNF Study of Immunogenicity and Sustained Response (OASIS-IBD): Analysis of 40,000 Patient Years of Anti-TNF UseECCO'24Year: 2024
Authors: Al-Hillawi, L.(1,2)*;Liao, H.(3);Powell Doherty, R.(2);Bedke, N.(4);Azzu, H.(5);Cripps, S.(5);Prabhu, A.(1);White, L.(1);Ambrose, T.(1);Cheung, V.(1);Palmer, R.(1);Walsh, A.(1,2);Travis, S.(6);Ternette, N.(2,7);Brain, O.(1,2);Satsangi, J.(1,2);
(1)Oxford University Hospitals NHS Foundation Trust, Department of Gastroenterology- John Radcliffe Hospital, Oxford, United Kingdom;(2)University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom;(3)University of Oxford, Jenner Institute, Oxford, United Kingdom;(4)University of Oxford, Nuffield Department of Medicine- Center for Immuno-oncology, Oxford, United Kingdom;(5)Oxford University Hospitals NHS Foundation Trust, Pharmacy Department- John Radcliffe Hospital, Oxford, United Kingdom;(6)Kennedy Institute of Rheumatology, Biomedical Research Centre, Oxford, United Kingdom;(7)University of Oxford, Nuffield Department of Medicine - Centre for Cellular and Molecular Physiology, Oxford, United Kingdom;The Oxford Anti-TNF Study of Immunogenicity and Sustained Response (OASIS-IBD)
